Development of viral vectors for use in cardiovascular gene therapy.

Viruses · 2010 · PMC3185614 · PMID 21994642

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In the earliest study of intracoronary injection of AdFGF-4 (AGENT-2), delivery of active vector by subselective coronary catheterization of culprit arteries resulted in a borderline significant reduction in the size of the region of myocardium demonstrating stress hypoperfusion eight weeks post-delivery [ 145 ].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.